CapsoVision (CV) Return on Capital Employed (2025)

CapsoVision (CV) reported Return on Capital Employed of 141.65% for Q4 2025, up 20.5% sequentially from 178.17% in Q3 2025.

CapsoVision (CV) Return on Capital Employed (2025) Analysis & Trends

CapsoVision (CV) has 1 years of Return on Capital Employed data on file, last reported at 141.65% in Q4 2025.

For the quarter ending Q4 2025, Return on Capital Employed changed N/A year-over-year to 141.65%; the trailing twelve-month figure through Dec 2025 stood at 141.65% (changed N/A YoY), and the FY2025 full-year result was 195.43%, changed N/A from the prior year.
Return on Capital Employed climbed to 141.65% in Q4 2025, from 178.17% in the prior quarter.
In the past five years, Return on Capital Employed ranged from a high of 141.65% in Q4 2025 to a low of 227.37% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	9.61%
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	12.24%
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	8.02%
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	9.62%
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	11.13%
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	24.24%
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	8.38%
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	9.30%
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	CapsoVision	162.07 Mn	151.95 Mn	1.95 Mn	-141.65%

Download Data